List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 80 studies with search of: zevalin lymphoma
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Active, not recruiting Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Lymphoma
Interventions: Drug: Rituximab;   Drug: Zevalin
2 Active, not recruiting Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Fludarabine;   Drug: Mitoxantrone;   Drug: Rituximab;   Drug: Zevalin
3 Active, not recruiting Study Of Yttrium-Ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
Condition: Lymphoma, Mantle-Cell
Interventions: Drug: Yttrium-ibritumomab (Zevalin);   Drug: Rituximab
4 Active, not recruiting Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
Condition: Lymphoma
Interventions: Drug: Zevalin;   Drug: Rituximab;   Drug: ^111 In Ibritumomab Tiuxetan
5 Recruiting Zevalin® First Line in Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab;   Drug: Rituximab
6 Active, not recruiting Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
Condition: Lymphoma
Interventions: Drug: Ibritumomab Tiuxetan (Zevalin);   Drug: Rituximab
7 Recruiting Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
Condition: Lymphoma
Interventions: Drug: Fludarabine;   Drug: Mitoxantrone;   Drug: Rituximab;   Drug: Zevalin;   Drug: Dexamethasone
8 Completed Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Low-Grade
Intervention: Drug: ibritumomab tiuxetan (Zevalin®)
9 Recruiting Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: 90Y-ibritumomab tiuxetan (Zevalin)
10 Not yet recruiting Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )
11 Recruiting Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
Conditions: Diffuse Large Cell Lymphoma;   Lymphoma
Interventions: Drug: Zevalin;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Drug: Rituximab;   Procedure: Stem Cell Transplant
12 Active, not recruiting A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas
Conditions: Primary Non-Hodgkin-Lymphoma;   Refractory Non-Hodgkin-Lymphoma;   CD20+ Aggressive Non-Hodgkin`s Lymphoma
Intervention: Drug: Zevalin
13 Recruiting Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-Based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)
Conditions: Diffuse Large B-Cell Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: Ibritumomab Tiuxetan (Zevalin)
14 Recruiting Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)
15 Not yet recruiting Zevalin and BEAM High-Dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin’s Lymphoma
Condition: Non-Hodgkin’s Lymphoma
Intervention: Drug: 90Yttrium Ibritumomab Tiuxetan (Zevalin)
16 Recruiting Zevalin-beam for Aggressive Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: ibritumomab tiuxetan
17 Active, not recruiting Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: darbepoetin alfa;   Biological: filgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Radiation: indium In 111 ibritumomab tiuxetan;   Radiation: yttrium Y 90 ibritumomab tiuxetan
18 Completed Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma
Condition: B-Cell Lymphoma
Intervention: Drug: Zevalin plus BEAM
19 Active, not recruiting Autologous Stem Cell Transplantation (ASCT) With Zevalin Plus Busulfan, Cyclophosphamide and Etoposide (BuCyE) in B-Cell Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Zevalin;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Etoposide
20 Recruiting Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
Condition: Non-Hodgkins Lymphoma
Interventions: Drug: Rituximab;   Drug: 90Y ibritumomab tiuxetan (Zevalin);   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Non myeloablative allogeneic stem cell transplantation

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services